Four hour quantitative real time polymerase chain reaction based comprehensive chromosome screening and accumulating evidence of accuracy safety predictive value and clinical efficacy
This review summarizes the accumulated experience with the development and clinical application of a 4-hour blastocyst quantitative real-time polymerase chain reaction–based comprehensive chromosome screening technology.
Nathan R. Treff, Ph.D., Richard T. Scott, Jr., M.D.
Volume 99, Issue 4, Pages 1049-1053, 15 March 2013
Embryonic comprehensive chromosomal euploidy may represent a powerful biomarker to improve the success of IVF. However, there are a number of aneuploidy screening strategies to consider, including different technological platforms with which to interrogate the embryonic DNA, and different embryonic developmental stages from which DNA can be analyzed. While there are advantages and disadvantages associated with each strategy, a series of experiments producing evidence of accuracy, safety, clinical predictive value, and clinical efficacy indicate that trophectoderm biopsy and quantitative real-time (q)PCR-based comprehensive chromosome screening (qPCR based-CCS) may represent a useful strategy to improve the success of IVF. This Biomarkers in Reproductive Medicine special issue review will summarize the accumulated experience with the development and clinical application of a 4-hour blastocyst qPCR based-CCS technology.